How AI and RWD Are Reshaping Orphan Drug Commercialization

It’s estimated that orphan drugs will account for more than 20% of global drug sales by 2032, when their total market value is forecast to exceed $400 billion. This rare disease boom has made it increasingly important for drug developers to find, understand, and engage the right patients at the right time — long before launch.

This report explores how AI-powered real-world data (RWD) analysis is transforming drug development and commercialization, offers specific examples of early disease detection enabled by RWD analysis, and examines how these insights can drive business value for pharma and improve patient outcomes. Read now to learn more about:

• RWD and orphan drug development
• The unmet need in rare disease
• Choosing fit-for-purpose RWD
• Operationalizing diagnostic insights

​​